Statement of Work for Supplemental Analytical Services between Radius Health, Inc. and Lonza Sales AG (Abaloparatide)

Summary

This agreement is between Radius Health, Inc. and Lonza Sales AG for supplemental analytical services related to the product Abaloparatide. Lonza will perform concentration testing on 10 samples and reissue a certificate of analysis using updated methods. The work must be completed by February 5, 2016, and payment is due in full upon completion. Certain pricing and proprietary details have been omitted for confidentiality.

EX-10.1 2 a16-6577_1ex10d1.htm EX-10.1

Exhibit 10.1

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Statement of Work

 

To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated 16 of October 2007

 

Supplemental analytical services

 

Number

 

RDS-001-SC003

 

 

Product Code/Name

 

RDS-001 Abaloparatide

 

 

Description of the proposed change

 

Supplemental services requested by Radius:

1)             Concentration testing with FG2 on 10 samples from Bioagilytix

2)             Reissue CoA of reference standard 8AK1R data with current TG2/FG2 and M-076 methods

 

 

 

Price Agreed

 

1.              [*]

2.              [*]

 

Total: [*]

 

 

Radius

 

Name: Naveen Palwai

Signature: /s/ Naveen Palwai

 

Date: 02/03/2016

Radius

 

Name: Wajiha Khan

Signature: /s/ Wajiha Khan

 

Date: 02/03/2016

Lonza Sales AG

 

Name: Paul Tastenhoye

Signature: /s/ Paul Tastenhoye

 

Date: 29/01/2016

Lonza Sales AG

 

Name: Frederique Mutterer

Signature: /s/ Frederique Mutterer

 

Date: 29/01/2016

 

Additional notes: /

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1



 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Detailed description of the proposed change

 

Activity 1: Concentration testing with FG2 on 10 samples from Bioagilytix + issue of an official test report.

Activity 2: Reissue CoA of reference standard 8AK1R data with current TG2/FG2 and M-076 methods

 

Timescale

 

By February 5th 2016

 

Price and Terms of Payment

 

1. Price

 

·              Activity 1: [*]€

·               Activity 2: [*]€

·               Total price: [*]€

 

2.              Payment

 

100% upon completion

 

oooOOOooo

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

2